Prescription drug · ANDA
bumetanide NDC 71335-1692
Bumetanide 1 mg/1 · Tablet · Oral · Bryant Ranch Prepack
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71335-1692-1 | 71335169201 | 30 TABLET in 1 BOTTLE (71335-1692-1)Marketed from Aug 17, 2020 | |
| 71335-1692-2 | 71335169202 | 90 TABLET in 1 BOTTLE (71335-1692-2)Marketed from Dec 29, 2021 | |
| 71335-1692-3 | 71335169203 | 28 TABLET in 1 BOTTLE (71335-1692-3)Marketed from Dec 29, 2021 | |
| 71335-1692-4 | 71335169204 | 18 TABLET in 1 BOTTLE (71335-1692-4)Marketed from Dec 29, 2021 | |
| 71335-1692-5 | 71335169205 | 60 TABLET in 1 BOTTLE (71335-1692-5)Marketed from Dec 29, 2021 | |
| 71335-1692-6 | 71335169206 | 100 TABLET in 1 BOTTLE (71335-1692-6)Marketed from Dec 29, 2021 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- bumetanide
- Generic name (nonproprietary)
- bumetanide
- Active ingredients
- Bumetanide — 1 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Bryant Ranch Prepack
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 202900
- Marketing start
- Listing expires
- Other FDA classes
- Increased Diuresis at Loop of Henle (Physiologic effect)
- Identifiers
- Product ID 71335-1692_3bd5380a-6de4-47fa-92b1-9c3d3874a1eeSPL ID 3bd5380a-6de4-47fa-92b1-9c3d3874a1eeSPL set ID a60bfe5f-d0d6-4d15-a3de-32dc68e41af3RxCUI 197418UNII 0Y2S3XUQ5H
- Pharmacologic class
- Loop Diuretic
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471335169201followed by a unit qualifier and the quantityPackage 71335-1692-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. CONTRAINDICATIONS Bumetanide is contraindicated in anuria. Although bumetanide tablets can be used …
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 202900
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| bumetanide | Bumetanide .5 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-525 |
| bumetanide | Bumetanide 1 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-526 |
| bumetanide | Bumetanide 2 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 68382-527 |
| bumetanide | Bumetanide 1 mg/1 | TabletOral | A-S Medication Solutions | 50090-6138 |
| bumetanide | Bumetanide 2 mg/1 | TabletOral | A-S Medication Solutions | 50090-6137 |
| bumetanide | Bumetanide .5 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1024 |
| bumetanide | Bumetanide 1 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1025 |
| bumetanide | Bumetanide 2 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1026 |